STANDARD BIOTOOLS INC. (LAB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LAB currently has 388M outstanding shares. with significant dilution risk as 219M authorized shares could dilute existing holders by 56.3%. The company has diluted shareholders by 10.01% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 388.2M shares outstanding |
390M | 220M |
| Mar 16, 2026 |
10-K filing | 381.6M shares outstanding |
380M | 220M |
| Nov 04, 2025 |
10-Q filing | 382.6M shares outstanding |
380M | 220M |
| Aug 15, 2025 |
10-Q filing | 380.5M shares outstanding |
380M | 220M |
| May 06, 2025 |
10-Q filing | 378.2M shares outstanding |
380M | 220M |
| Mar 11, 2025 |
10-K filing | 353.2M shares outstanding |
350M | 220M |
| Nov 06, 2024 |
10-Q filing | 371.5M shares outstanding |
370M | 220M |
| Aug 06, 2024 |
10-Q filing | 372.3M shares outstanding |
370M | 220M |
| Jun 20, 2024 |
S-3 filing: The filing is an S-3 registration statement for the resale of up to 105,116,628 shares of common stock by selling securityholders. |
370M | 220M |
| May 09, 2024 |
10-Q filing | 372.1M shares outstanding |
370M | 110M |
| Mar 18, 2024 |
8-K filing: Standard BioTools Inc. exchanged 127,780 shares of Series B-1 Convertible Preferred Stock and 127,779 shares of Series B-2 Convertible Preferred Stock for 92,930,553 shares of common stock on March 18, 2024. |
290M | 110M |
| Mar 01, 2024 |
10-K filing | 290.1M shares outstanding |
290M | 110M |
| Feb 02, 2024 |
S-3/A filing: This is an S-3/A filing. The filing discusses the determination of the registrant's liability under the Securities Act for a primary offering of securities. |
79M | 110M |
| Jan 19, 2024 |
S-3 filing: This S-3 filing relates to the offer and sale from time to time by the selling securityholders of up to 26,392,931 shares of Standard BioTools Common Stock, and the offer and sale of up to 11,691,989 shares of Standard BioTools Common Stock that are issuable upon the exercise of warrants. |
79M | 110M |
| Nov 07, 2023 |
10-Q filing | 79.2M shares outstanding |
79M | 75M |
| Aug 08, 2023 |
10-Q filing | 78.7M shares outstanding |
79M | 75M |
| May 09, 2023 |
10-Q filing | 79.1M shares outstanding |
79M | 75M |
| Mar 14, 2023 |
10-K filing | 78.3M shares outstanding |
78M | 75M |
| Nov 09, 2022 |
10-Q filing | 78.9M shares outstanding |
79M | 75M |
| Aug 09, 2022 |
10-Q filing | 77.8M shares outstanding |
78M | 75M |
| May 17, 2022 |
S-3 filing: The filing relates to the registration of 75,164,397 shares of common stock offered by selling securityholders, which may be issued upon conversion of Series B Convertible Preferred Stock. |
77M | 75M |
| May 09, 2022 |
10-Q filing | 77.0M shares outstanding |
77M | 0 |
| Mar 08, 2022 |
10-K filing | 75.8M shares outstanding |
76M | 0 |
| Nov 09, 2021 |
10-Q filing | 76.3M shares outstanding |
76M | 0 |
| Aug 06, 2021 |
10-Q filing | 75.5M shares outstanding |
75M | 0 |
| May 07, 2021 |
10-Q filing | 75.0M shares outstanding |
75M | 0 |
| Feb 25, 2021 |
10-K filing | 74.5M shares outstanding |
75M | 0 |
| Nov 09, 2020 |
10-Q filing | 74.1M shares outstanding |
74M | 0 |
| Aug 07, 2020 |
10-Q filing | 71.3M shares outstanding |
71M | 0 |
| May 11, 2020 |
10-Q filing | 70.0M shares outstanding |
70M | 0 |
| Feb 27, 2020 |
POS AM filing: Fluidigm Corporation may offer common stock, preferred stock, debt securities, warrants to purchase common stock or preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities up to an aggregate amount of $125,000,000. |
N/A | 0 |
| Feb 27, 2020 |
10-K filing | 49.3M shares outstanding |
49M | 0 |